Rennova Health, a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers, has signed a definitive agreement to acquire the remaining ownership of approximately 85 percent of Genomas.
The acquisition brings to Rennova PhyzioType Systems for DNA-guided management and prescription of drugs used to treat mental illness, pain, heart disease and diabetes.
Rennova in July announced the acquisition of approximately 15 percent of Genomas.
Rennova Health has previously partnered with Genomas on the launch of a series of pharmacogenetics tests that are performed in Genomas’ laboratory via an FDA-approved in vitro diagnostic (IVD) genotyping kit.
The laboratory will remain on site at Hartford Hospital and Gualberto Ruaño will continue to serve as the president and medical director of Genomas, which will become a wholly owned subsidiary of Rennova Health.
“The acquisition of Genomas is a continuation of our goal to assist practitioners by providing better diagnostics to enable them to deliver personalized medicine and improved patient outcomes,” said Seamus Lagan, CEO of Rennova Health.
“This acquisition allows Rennova to deliver diagnostic results that use DNA-guided management and selection of drugs used to treat mental illness, pain, heart disease and diabetes. Genomas’ PhyzioType Systems provide physicians with an unprecedented capability to reduce risk and select the safest and most effective drug to achieve treatment goals and enhance patient compliance. This will also reduce healthcare costs.”
“We expect the Genomas’ tests to become an increasingly important part of our overall business in the coming months,” Lagan added.
Rennova Health, US, Genomas, Healthcare, Risk management, Diagnostics, M&A, PhyzioType, Seamus Lagan